• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Rituximab
    2 Drugs classified under this active ingredient

    All the Active Ingredient Drugs

    partial basket chart

    Monoclonal Antibody. Rituximab 10 mg/ml.
    VIALS (conc. for sol. for infus.): 2 x 100
    mg/10 ml; 1 x 500 mg/50 ml. NHL: 375
    mg/m2 as cont. infus: In prev. untreat.
    pts: In comb. with chemother. given on
    day 1 of ea. cycle for 8 cycles. In
    relapsed/refract. pts: As single agent 1
    wkly for 4 doses. Prev. untreat. pts:
    Mainten. ther: 375 mg/m2 bdy surface
    1 x every 2 mths until dis. progr./max.
    2 yrs. Pts. respond. to induct. tmt. may
    receive maint. ther. at 375 mg/m2 bdy
    surface 1 x every 3 mths until dis.
    progress or for max. period 2 years.
    Chron. lymphocytic leuk. (CLL): 375
    mg/m2 on day 1 of 1st tmt cycle, foll.
    by 500 mg/m2 on day 1 of ea.
    subsequent cycle for 6 cycles total.
    ANCA-associated Vasculitis (AAV): 375
    mg/m2 body surface, as I.V. infus 1 x
    wkly for 4 wks. Methylprednisolone
    1,000 mg I.V. dly for 1-3 days is
    recommend. to treat severe vasculitis
    sympts, follow. by oral prednisone 1
    mg/kg/day (max. 80 mg/day), and
    tapered as rapidly as poss. per clin.
    need) during and aft. tmt.
    Tmt. previous untreated pts. with III-IV
    follicular lymphoma in comb. with
    chemother. Tmt. relapsed or refract. lowgrade
    or follicular B-cell non-Hodgkin’s
    lymphoma, CD20 positive diffuse large
    B-cell non-Hodgkin’s lymphoma in comb. with CHOP chemother. Maint. ther. for
    tmt. follic. lymphoma pts. respond. to
    induct. ther. First line tmt. chron.
    lymphocytic leuk. (CLL) in comb. with
    chemother. Rheum. arthrit: In comb. with
    methotrexate, to reduce signs and sympts.
    in adult pts. with mod-severe active RA
    who had inad. response/intol. to one or
    more TNF antagonist ther. ANCAassociated
    vasculitis (AAV): In combinat.
    with glucocorticoids, tmt. of adults with
    Wegener’s Granulomatosis (WG) and
    Microscopic Polyangiitis (MPA).

    partial basket chart

    Monoclonal Antibody. Rituximab 100 mg, 500 mg.
    VIAL (concentr. for sol. for infus.): 1×50ml, 2×10ml. Dosage must be adjust. individ. for each pt.
    CLL: In comb. with chemother. is indic. for the tmt. of pts. with previos. untreated and relapsed/refract. CLL. Only limited data are available on effic. and safety for pts. previous. treated with MABs include. rituximab or pts. refract. to prev. rituximab plus chemother.
    Granulomatosis with polyangiitis and microscopic polyangiitis.
    In combin. with glucocorticoids, is indic. for the tmt. of adult pts. with granulomatosis with polyangiitis (GPA) (Wegener’s Granulomatosis (WG)) & microscopic polyangiitis (MPA).
    C/I: For use in CLL: Hypersens., Active, sev. infec., Pts. in a sev. immunocomprom. state. For use in granulomatosis with polyangiitis and microscopic polyangiitis: Hypersens. to the active subst./murine proteins., Active, sev. infec., Pts. in a sev. immunocomprom. state., Severe HF (New York Heart Association Class IV) or sev., uncontrol. cardiac dis.